Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ:AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech’s shares are taking flight today in response to a successful interim analysis for Merck‘s oral COVID-19 pill, molnupiravir, in a late-stage trial.
Atea, for its part, is also trialing an oral COVID-19 medication, known as AT-527, with a broadly similar mechanism of action (they both interfere with viral replication). AT-527 is being evaluated as a treatment for patients who are already infected with COVID-19.
While the idea that Merck’s promising interim results are somehow a harbinger of things to come for AT-527 is a bit of a stretch, Wall Street is enthusiastic about its commercial prospects. Current peak sales estimates range from a low of $2.3 billion to a high of $4 billion. Either one of those way-too-early revenue forecasts would be an enormous payday for a company with a market cap under $4 billion right now. Investors, however, seem to be taking this Merck news as as positive sign that AT-527 will eventually become a key therapy in the fight against COVID-19.
Is Atea’s stock a buy on this news? COVID-19 stocks — especially ones with important new therapies — can produce jaw-dropping returns in the blink of an eye. There’s no doubt about that at this point in the pandemic. So it might not be a bad idea to buy a few shares of this red-hot biotech stock today. That said, it’s probably best to keep your position small.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.